- Home
- SHLS vs OLMA Comparison
SHLS vs OLMA Comparison
Compare SHLS & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SHLS | OLMA |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SHLS | OLMA |
|---|---|---|
| Price | $7.91 | $14.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 10 |
| Target Price | $9.07 | ★ $44.89 |
| AVG Volume (30 Days) | ★ 4.7M | 751.6K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.86 | 15.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $475,331,000.00 | N/A |
| Revenue This Year | $26.24 | N/A |
| Revenue Next Year | $11.52 | N/A |
| P/E Ratio | $41.63 | ★ N/A |
| Revenue Growth | ★ 19.07 | N/A |
| 52 Week Low | $3.81 | $3.89 |
| 52 Week High | $11.36 | $36.26 |
Technical Indicators
Market Signals| Indicator | SHLS | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 63.78 | 38.26 |
| Support Level | $7.24 | $13.11 |
| Resistance Level | $9.80 | $17.23 |
| Average True Range (ATR) | 0.51 | 0.75 |
| MACD | 0.11 | -0.04 |
| Stochastic Oscillator | 59.25 | 16.89 |
Price Performance
Historical ComparisonAbout SHLS Shoals Technologies Group Inc.
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.